Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Doxorubicin and cyclophosphamide (AC) + bevacizumab|DRUG: Docetaxel (T) + bevacizumab|DRUG: Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab|DRUG: Docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab|DRUG: Bevacizumab and trastuzumab maintenance therapy|DRUG: Bevacizumab maintenance therapy
Sponsor: Sanofi